XML 58 R48.htm IDEA: XBRL DOCUMENT
v3.23.3

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | 36 Months Ended | 84 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Oct. 31, 2023 USD ($) right $ / shares | Feb. 28, 2023 USD ($) | Mar. 31, 2023 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Sep. 30, 2023 USD ($) | Dec. 31, 2026 | Dec. 31, 2023 | Jun. 30, 2024 USD ($) | Dec. 31, 2022 USD ($)
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment to extinguish future royalty obligation |  |  |  |  | $ 295 |  |  |  |  |  |
Turning Point |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  | $ 3,300 |  |  |  |  |  |  |
Total consideration |  |  |  | $ 4,100 |  |  |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Business combination, contingent value, number of rights received | right | 1 |  |  |  |  |  |  |  |  |  |
Subsequent Event | Mirati Therapeutics |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Share price (in usd per share) | $ / shares | $ 58.00 |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred | $ 4,800 |  |  |  |  |  |  |  |  |  |
Business combination, contingent value, share price (in dollars per share) | $ / shares | $ 12.00 |  |  |  |  |  |  |  |  |  |
Continent consideration liability |  |  |  |  |  |  |  |  |  | $ 1,000 |
Keytruda royalties | Forecast |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of net sales payable to alliance partner |  |  |  |  |  |  |  |  | 6.50% |  |
Keytruda royalties | Forecast | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of net sales payable to alliance partner |  |  |  |  |  |  |  | 2.50% |  |  |
Nimbus Therapuetics TYK2 Inhibitor |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Proceeds from legal settlements |  |  |  |  |  | $ 40 | $ 400 |  |  |  |
Contingent sales-based milestones |  | $ 2,000 |  |  |  |  |  |  |  |  |
Other |  |  | $ 400 |  |  |  |  |  |  |  |
LianBio Co. Ltd. | Mavacamten Rights | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments to acquire rights | $ 350 |  |  |  |  |  |  |  |  |  |
Bristol-Myers Squibb | Keytruda royalties | Forecast | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment and royalty allocation |  |  |  |  |  |  |  | 75.00% |  |  |
Ono | Keytruda royalties | Forecast | Subsequent Event |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment and royalty allocation |  |  |  |  |  |  |  | 25.00% |  |  |
Immatics |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payments |  |  |  |  |  | 150 |  |  |  |  |
Contingent and regulatory milestone payments |  |  |  |  |  | 770 |  |  |  |  |
Dragonfly |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payments |  |  |  |  |  | $ 175 |  |  |  |  |
Nimbus Therapeutics |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payments |  | $ 4,000 |  |  |  |  |  |  |  |  |
Nimbus Therapeutics | Nimbus Therapuetics TYK2 Inhibitor |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Change in control proceeds |  |  |  |  |  | 10.00% |  |  |  |  |
Percentage of ownership acquired |  | 100.00% |  |  |  |  |  |  |  |  |
Mature products and other | Discontinued Operations, Held-for-sale |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Assets held for sale |  |  |  |  |  |  |  |  |  |  | $ 172
Liabilities held for sale |  |  |  |  |  |  |  |  |  |  | 20
Mature products and other | Cost of products sold |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Asset impairment charges |  |  |  |  | $ 43 |  |  |  |  |  |
Mature products and other | LOTTE Corporation |  |  |  |  |  |  |  |  |  |  |
Licensing Arrangements [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales price |  |  |  |  |  |  |  |  |  |  | $ 159

X
- Definition Asset Acquisition, Percentage of Ownership Acquired + References No definition available. + Details
Name: | bmy_AssetAcquisitionPercentageOfOwnershipAcquired
Namespace Prefix: | bmy_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Number Of Rights Received Per Share + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValueNumberOfRightsReceived
Namespace Prefix: | bmy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Contingent Value, Share Price + References No definition available. + Details
Name: | bmy_BusinessCombinationContingentValueSharePrice
Namespace Prefix: | bmy_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement Contingent Payments Maximum Exposure + References No definition available. + Details
Name: | bmy_CollaborativeArrangementContingentPaymentsMaximumExposure
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent and Regulatory Milestone Payments + References No definition available. + Details
Name: | bmy_ContingentAndRegulatoryMilestonePayments
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License and Other Arrangements Upfront Payments + References No definition available. + Details
Name: | bmy_LicenseAndOtherArrangementsUpfrontPayments
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Licensing Arrangements + References No definition available. + Details
Name: | bmy_LicensingArrangementsLineItems
Namespace Prefix: | bmy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment And Royalty Allocation + References No definition available. + Details
Name: | bmy_PaymentAndRoyaltyAllocation
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment To Extinguish Future Royalty Obligation + References No definition available. + Details
Name: | bmy_PaymentToExtinguishFutureRoyaltyObligation
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments To Acquire Rights + References No definition available. + Details
Name: | bmy_PaymentsToAcquireRights
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage Of Net Sales Payable To Alliance Partner + References No definition available. + Details
Name: | bmy_PercentageOfNetSalesPayableToAlliancePartner
Namespace Prefix: | bmy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Settlement, Contingent Development, Change In Control Proceeds + References No definition available. + Details
Name: | bmy_SettlementContingentDevelopmentChangeInControlProceeds
Namespace Prefix: | bmy_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details
Name: | us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11 + Details
Name: | us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of income related to nonoperating activities, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_OtherNonoperatingIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received for the settlement of litigation during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromLegalSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_TurningPointMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bmy_MiratiTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bmy_LicensingAndOtherArrangementsAxis=bmy_KeytrudaRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bmy_LicensingAndOtherArrangementsAxis=bmy_NimbusTherapueticsTYK2InhibitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_LianBioCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bmy_LicensingAndOtherArrangementsAxis=bmy_MavacamtenRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_OnoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_ImmaticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_DragonflyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_NimbusTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_MatureBrandsAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bmy_LOTTECorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |